Conflicts of interest: SV has received travel grants from Abbott, BMS, Boehringer-Ingelheim, Gilead Sciences, Roche, Tibotec and ViiV Healthcare.

FW has received travel grants from Abbott, BMS, Boehringer-Ingelheim, Gilead Sciences, Roche, Tibotec and ViiV Healthcare. GM has received research grants from Abbott, Ardea Biosciences, Bionor, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck, Pfizer, Theratechnologies and Tibotec. He has received honoraria as a speaker and/or advisor from Astellas, Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Selleck Ruxolitinib Merck, Pfizer, Theratechnologies, Tibotec and ViiV Healthcare. FR received research funding or honoraria from, or consulted for, Bristol-Myers Squibb, Gilead Sciences and Roche. DJ has received

research grants from Tibotec, ViiV and Vertex. He has received honoraria as a speaker from Tibotec, BMS, Merck, BIPI and Gilead and as a consultant for Tibotec, Roche and Gilead. SM has received research grants from Roche and has served on advisory boards for ViiV, BMS and Gilead. He has received honoraria as a speaker from Roche, Tibotec, BMS and Gilead. CK has received travel grants, conference fees or consultancy fees from Abbott, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Janssen and MSD. MF has served as a scientific advisor for, and/or received honoraria for speaking engagements from, Abbott, Boehringer selleck kinase inhibitor Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Theratechnologies, Methisazone Tibotec and ViiV Healthcare. LS has received lecture fees, travelling expenses and payment of registration fees from Roche, Bristol-Myers Squibb, MSD, Gilead and Boehringer Ingelheim. DH has received research grants from Pfizer, Tibotec, Gilead and Bionor, and honoraria for advisory boards/consulting from Tibotec, Pfizer, ViiV, Gilead, Monogram and Merck. EDJ has served on the speakers bureau for Gilead Sciences, Merck, Tibotec and Virco and has received honoraria for consulting from Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck, Tibotec, and Vertex Pharmaceuticals. He has received research support from

Abbott Laboratories, Achillion, Avexa, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Hoffman LaRoche Laboratories, Merck, Pfizer, Schering Plough, Taimed, Tobira, Tibotec and Vertex. PR has served as a scientific advisor to Boehringer Ingelheim Pharmaceuticals, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck & Co., Theratechnologies, Tibotec Therapeutics and Tobira Therapeutics. He has served on data and safety monitoring boards and endpoint adjudication committees for Tibotec Therapeutics and has received honoraria for speaking engagements at scientific conferences from Boehringer Ingelheim Pharmaceuticals, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline and Theratechnologies.